PLoS Biology (Jan 2022)

DAJIN enables multiplex genotyping to simultaneously validate intended and unintended target genome editing outcomes.

  • Akihiro Kuno,
  • Yoshihisa Ikeda,
  • Shinya Ayabe,
  • Kanako Kato,
  • Kotaro Sakamoto,
  • Sayaka R Suzuki,
  • Kento Morimoto,
  • Arata Wakimoto,
  • Natsuki Mikami,
  • Miyuki Ishida,
  • Natsumi Iki,
  • Yuko Hamada,
  • Megumi Takemura,
  • Yoko Daitoku,
  • Yoko Tanimoto,
  • Tra Thi Huong Dinh,
  • Kazuya Murata,
  • Michito Hamada,
  • Masafumi Muratani,
  • Atsushi Yoshiki,
  • Fumihiro Sugiyama,
  • Satoru Takahashi,
  • Seiya Mizuno

DOI
https://doi.org/10.1371/journal.pbio.3001507
Journal volume & issue
Vol. 20, no. 1
p. e3001507

Abstract

Read online

Genome editing can introduce designed mutations into a target genomic site. Recent research has revealed that it can also induce various unintended events such as structural variations, small indels, and substitutions at, and in some cases, away from the target site. These rearrangements may result in confounding phenotypes in biomedical research samples and cause a concern in clinical or agricultural applications. However, current genotyping methods do not allow a comprehensive analysis of diverse mutations for phasing and mosaic variant detection. Here, we developed a genotyping method with an on-target site analysis software named Determine Allele mutations and Judge Intended genotype by Nanopore sequencer (DAJIN) that can automatically identify and classify both intended and unintended diverse mutations, including point mutations, deletions, inversions, and cis double knock-in at single-nucleotide resolution. Our approach with DAJIN can handle approximately 100 samples under different editing conditions in a single run. With its high versatility, scalability, and convenience, DAJIN-assisted multiplex genotyping may become a new standard for validating genome editing outcomes.